Table 1:

Exemplar approaches to measure and manage contributors to long-term outcomes in recovering AME patients.

MOTOR FUNCTION	mRS NEOS CASE† Biofluid and Neuroimaging biomarkers	Neurology; PMR, OT/PT	Rehabilitation services
COGNITION	MoCA Neuropsychological testing CSF biomarkers	Neurology Psychiatry Neuropsychology	Cognitive rehabilitation
PSYCHOSIS, DEPRESSION, ANXIETY	PHQ-9 GAD-7	Neurology Psychiatry Neuropsychology	CBT psychotropic medications
FATIGUE	FSMC MFIS	Neurology Psychiatry PMR, OT/PT Family Medicine	Cognitive rehabilitation
SLEEP	ESS; PSQI polysomnography	Sleep Medicine	Pharmacologic approach; Behavioral therapy
SEIZURES	EEG	Epilepsy specialist	Anticonvulsant therapies

^†An AE severity scale that assesses 9-items (seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, and motor weakness) on a 3-point scale, yielding a total CASE score of 0-27 points.(64)

AME = Antibody-Mediated Encephalitis; mRS = modified Rankin Scale; NEOS = anti-NMDAR Encephalitis one-Year Functional Status score; CASE = Clinical Assessment of Scale in Autoimmune Encephalitis score; PMR = Physical Medicine & Rehabilitation; OT = Occupational Therapy; PT = Physical Therapy; EEG = electroencephalogram; MoCA = Montreal Cognitive Assessment; CSF = cerebrospinal fluid; PHQ-9 = Patient Health Questionnaire-9; GAD-7 = General Anxiety Disorder-7; CBT = Cognitive-behavioral therapy; FSMC = Fatigue Scale for Motor and Cognitive Function; MFIS = Modified Fatigue Impact Scale; ESS = Epworth Sleepiness Scale; PSQI = Pittsburgh Sleep Quality Index